Caprion Pharmaceuticals says the FDA has granted fast track status to Shigamabs to prevent infection with shigatoxin-producing bacteria. Caprion plans to launch a pivotal Phase II/III trial in early 2007. Report
Deal-Making Insights for the Life Sciences Industry
Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.